156TiP RASolve 301: A phase III study of daraxonrasib (RMC-6236) vs. docetaxel in previously treated RAS-mutant non-small cell lung cancer (NSCLC)

Previously treated NSCLC patients represent a significant unmet medical need. RAS mutations occur in ∼30% of NSCLC cases, with non-G12C variants making up 60%. Most of these are G12X mutations, for which no approved targeted therapies are available. In an ongoing phase I monotherapy trial (NCT05379985), daily oral daraxonrasib (RMC-6236; 120–220 mg), a RAS(ON) multi-selective, tri-complex inhibitor of GTP-bound mutant and wild-type RAS, showed manageable safety and preliminary efficacy in NSCLC.